Page 99 | Certara

Case Study

Using Modeling & Simulation to Develop a Dosing Regimen for a Bispecific Antibody for Pediatric Cancer

Bispecific antibodies are an emerging class of antibodies developed in recent years that provide new…

CertaraJanuary 23, 2023

Blog

Tips & Tricks for Streamlining Non-compartmental Pharmacokinetic Analysis

These Phoenix tips and tricks will help you exclude Lambda Z, name partial areas, and…

CertaraJanuary 20, 2023

On-Demand Webinar

D360 as your organization’s extendable and central data engine

D360 is an industry-leading scientific data informatics platform providing a flexible, scalable, and customizable enterprise…

CertaraJanuary 20, 2023

Conference

PAGE 2025

June 4-6, 2025 - Thessaloniki, Greece - Booth 11 & 12

CertaraJanuary 16, 2023

On-Demand Webinar

Physiologically-Based Pharmacokinetic Modeling & Simulation to Support Asciminib NDA Submission & Inform Drug Product Label

Physiologically based pharmacokinetic (PBPK) modeling and simulation has become an established approach to assess drug-drug…

CertaraJanuary 13, 2023

Blog

New FDA Validator Rules V1.6 Explained

In this blog, we explore what you need to know about the update to the…

CertaraJanuary 12, 2023

Video

Simcyp Secondary Intelligence Software

Introducing Secondary Intelligence. The first and only evidence based quantitative technology for managing off target…

CertaraJanuary 10, 2023

Announcement

Certara Awarded NIH Contract for Toxicology Consulting Support

Certara toxicology experts to support NIH’s BPN and HEAL drug development programs for nervous system…

CertaraJanuary 10, 2023

Video

If your drug is a CYP3A substrate, we have good news for you!

CertaraJanuary 9, 2023

Announcement

Ghent University wins the 2021/22 Certara-Simcyp Grant and Partnership Scheme

PRINCETON, N.J., January 9, 2023 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation,…